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ABSTRACT
Novel tests (BioPlex) for herpes simplex virus-1 (HSV-1) and HSV-2 IgG were compared with
HerpeSelect HSV-1 and HSV-2 ELISAs for type-speciﬁc IgG. The sensitivity and speciﬁcity of BioPlex
HSV-1 IgG were 94% (84 ⁄ 89) and 96% (119 ⁄ 124), respectively, with unselected sera, while the sensitivity
and speciﬁcity of BioPlex HSV-2 IgG were 92% (109 ⁄ 118) and 98% (95 ⁄ 97), respectively. BioPlex IgM
was compared with Diamedix IgM against sera from patients with culture-documented genital herpes.
The test results were concordant in 81% of sera from HSV-1 patients and in 90% of sera from HSV-2
patients. Use of BioPlex IgM in addition to BioPlex IgG tests increased HSV-2 seroconversion detection
from 47% of subjects to 70%. Use of Diamedix IgM in addition to Focus IgG ELISA increased HSV-2
detection from 40% of subjects to 70%. IgM was detected by BioPlex in 63% of sera from patients with
early HSV-2 infection (< 30 days) and in 59% of sera by Diamedix. IgM was also detected in a large
proportion of sera from subjects with established HSV-2 infection (33% by BioPlex and 29% by
Diamedix). Addition of IgM testing substantially increased the ability to detect seroconversion early in
infection. IgM is an indicator of recent infection only in subjects who lack detectable IgG.
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INTRODUCTION
Type-speciﬁc antibody testing for herpes simplex
virus (HSV) is a useful tool for diagnosing genital
herpes in symptomatic patients and in those who
do not have current symptoms [1]. A number of
studies have shown that tests for IgG that are
based on the type-speciﬁc proteins gG-1 (for HSV-
1) and gG-2 (for HSV-2) are the most accurate for
discriminating between infection with HSV-1 or
HSV-2 [2–4], and several such commercially avail-
able tests have been licensed by the US Food and
Drug Administration. These include HerpeSelect
HSV-1 and HSV-2 ELISAs, HerpeSelect HSV-1
and -2 Immunoblot, biokitHSV-2 point of care test
(previously the POCkit HSV-2 test), and Captia
HSV-1 and -2 ELISAs. Recently, a novel ﬂuores-
cent bead immunoassay, based on a unique, ﬂoor-
standing automated analyser, BioPlex 2200, has
been developed. These tests detect IgG to gG-1
and gG-2, and a non-typing format for HSV IgM
detection is also available. This technology has
been used previously for detecting antibodies to
Epstein–Barr virus and Toxoplasma gondii [5,6].
Because as many as 22 different analyses can be
performed simultaneously on the instrument,
high-throughput testing is feasible for panels of
antibodies to HSV-1, HSV-2 and other potential
pathogens from oral or genital sites.
The present study was designed to assess the
performance of the gG-1- and gG-2-based BioPlex
IgG tests against the gG-based HerpeSelect tests,
with western blot (WB) as the ﬁnal arbiter of HSV
serostatus. Sera from individuals with new genital
HSV-1 or HSV-2 infections, as documented by
culture and by HSV WB serology, were then used
in BioPlex IgG and IgM tests to determine the
utility of the IgM test for detecting early serocon-
version. Finally, results from individuals with ﬁrst
episode infections were compared with results
from those having symptomatic recurrent HSV-2
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episodes in order to determine the ability of the
combined BioPlex IgG ⁄ IgM tests to discriminate
between new infections and established recurrent
infections with HSV-2. The comparator test
combination for studies on culture-documented
subjects was the HerpeSelect HSV-2 ELISA (for




Four sets of sera were used:
1. All-comers sera: a set of 216 sera submitted to the University
of Washington Virology laboratory for type-speciﬁc HSV
serology testing was stripped of identiﬁers and coded for
testing by BioPlex IgG-HSV-1, BioPlex IgG-HSV-2 and
Bioplex IgM-HSV (Bio-Rad, Hercules, CA, USA), and by
the HerpeSelect HSV-1 and HSV-2 ELISAs (Focus HSV-1
and Focus HSV-2; Focus Diagnostics, Cypress, CA, USA).
Sera were also tested by WB [7].
2. First episode HSV-1 sera: Thirty-four sera from 22 HSV-
seronegative subjects with documented seroconversion to
HSV-1 were used to determine the ability of the IgG and
IgM tests, separately and in combination, to diagnose early
infection. Thirteen sera were obtained within 7 days of the
onset of genital herpes (early-phase), 13 were from mid-
phase (8–30 days post-onset), and eight were from later in
the episode (31–123 days; median 90 days).
3. First episode HSV-2 sera: To determine the ability of the
BioPlex HSV-2 IgG and IgM tests to detect early ﬁrst
episodes of HSV-2 infection, 52 sera from 30 subjects with
documented seroconversion to HSV-2 were tested. Of the 52
sera, 39 were from 26 individuals who had no HSV antibody
at disease onset, and 13 were from four subjects who had
HSV-1 antibody at HSV-2 disease onset. Twenty-seven sera
were from early-phase (0–7 days post-onset), 13 were from
mid-phase (8–30 days post-onset), and 12 were from late-
phase (32–149 days; median 100 days). All subjects contri-
buting sera to sets 2 and 3 had culture-documented infec-
tions and seroconverted to the infecting HSV type by WB.
4. Recurrent episode sera: A set of 55 sera from 48 patients with
culture-documented recurrent genital HSV-2 was tested for
the presence of IgM and ⁄ or IgG in established HSV-2
infection. These individuals had a history of genital herpes
and were positive by WB for HSV-2 before the episode from
which serum was used for this study. Sera were taken on
the day each subject presented to clinic with symptoms (day
0), or at a visit shortly thereafter (within 21 days of onset of
symptoms).
Subjects in groups 2–4 were enrolled in studies of genital
herpesat theUniversityofWashingtonVirologyResearchClinic
and gave informed consent under protocols approved by the
University of Washington Human Subjects Review Committee.
HSV serology
Testing by the BioPlex method for IgM and IgG was performed
by the manufacturer without any knowledge of the test results
by other methods or the clinical status of the subjects. BioPlex
HSV-1 IgG uses an in-house gG-1 recombinant protein, while
the HSV-2 test uses a synthetic c. 40-mer peptide fragment of
gG-2, representing an immunodominant epitope (amino-acids
547–582). The assays were performed on the BioPlex 2200
immunoassay analyser (Bio-Rad). Brieﬂy, for HSV-1 and HSV-
2 IgG, individual magnetic beads, coated with the recombinant
gG-1 protein or the peptide fragment of gG-2, were mixed with
5 lL of sample and sample diluent. For HSV-1 ⁄ 2 IgM,
individual magnetic beads, coated separately with cell lysate
antigens from HSV-1 and HSV-2, were mixed with 5 lL of
sample and IgM sample treatment buffer, which contains goat
anti-human IgG to remove human c-globulins and rheumatoid
factor. Sample mixtures were allowed to incubate at 37C for
20 min. After a series of wash cycles, anti-human antibody
conjugated to phycoerythrin was added and incubated at 37C
for 10 min. Following additional wash steps to remove excess
conjugate, the magnetic beads were passed through a detector.
HSV IgG and IgM concentrations are proportional to the
resulting ﬂuorescence intensity. The BioPlex 2200 provides
semiquantitative results in the form of arbitrary units or an
antibody index, with no claims to clinical relevance. An
antibody index < 1.0 is considered negative, while an antibody
index ‡ 1.0 is considered positive. Importantly, while IgM
beads are coated with HSV-1 or HSV-2 cell lysates, the results
are combined and are not intended to be type-speciﬁc.
Focus HSV-1 and HSV-2 ELISA 96-well test kits were used
according to the manufacturer’s instructions. Optical densities
of test wells were normalised by dividing by the mean optical
density of an in-kit equilibrator serum run in triplicate. Scores
< 0.9 were considered negative, and scores >1.1 were
considered positive. Results falling between 0.9 and 1.1 were
considered to be equivocal.
Diamedix IgM 96-well ELISA test kits (IVAX Diagnostics,
Miami, FL, USA) were used to test sera from groups 2, 3 and 4
according to the kit instructions.
RESULTS
Sensitivity and speciﬁcity of BioPlex
IgG-HSV-1
Of 216 sera from subjects without clinical or virus
culture data, three generated equivocal results in
the Focus HSV-1 IgG test and were not evaluated
further. Eighty-nine (42%) of the remaining 213
sera were positive for HSV-1 IgG by BioPlex or
Focus HSV-1 ELISA. The sensitivity of the BioPlex
test was 94% (84 ⁄ 89), with a speciﬁcity of 96%
(119 ⁄ 124) when the Focus HSV-1 ELISA was used
as the comparator. When WB analysis was used
as the comparator, the sensitivity of the BioPlex
test was 85% (89 ⁄ 105) and the speciﬁcity was 98%
(109 ⁄ 111), while the sensitivity of the Focus assay
was 83% (86 ⁄ 103) and the speciﬁcity was 97%
(107 ⁄ 110). Of the ten discordant sera, ﬁve were
positive by BioPlex but negative by Focus, and
ﬁve were negative by BioPlex but positive
by Focus. WB analysis conﬁrmed the result of
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BioPlex in six cases (three positive and three
negative), and conﬁrmed the Focus result in four
cases (two positive and two negative).
Sensitivity and speciﬁcity of BioPlex
HSV-2 IgG
Of 216 sera, one yielded an equivocal result by
Focus for HSV-2 IgG. Of the remaining 215 sera,
111 (52%) were positive by BioPlex and 118 (55%)
were positive by Focus. Compared with Focus,
the sensitivity of the BioPlex assay was 92%
(109 ⁄ 118) and the speciﬁcity was 98% (95 ⁄ 97),
while the sensitivity was 100% (107 ⁄ 107) and the
speciﬁcity was 95% (104 ⁄ 109) compared with
WB. WB analysis conﬁrmed the BioPlex test result
for ten (91%) of 11 discordant test results. Of 11
sera with discordant Biokit-Focus IgG results,
nine were negative by BioPlex and WB analysis,
but were positive by Focus.
Detection of IgM and IgG in early HSV-1
infections
The comparison data detailed above show that
the BioPlex tests are comparable in performance
to the licensed type-speciﬁc IgG ELISAs from
Focus. However, the sera tested were not from
previously characterised patients with a known
infection status. Therefore, the ability of the
BioPlex and Focus IgG assays to detect early
seroconversion was tested alone and in combina-
tion with IgM tests. Of the 26 sera drawn within
30 days of onset from 22 patients with ﬁrst
episode HSV-1 disease, 11 sera from nine patients
were IgM-positive. Seven of these 11 sera were
IgM-positive only by BioPlex (Table 1). Thus,
addition of the BioPlex IgM test increased the
sensitivity for detecting seroconversion to HSV-1
from three (14%) to nine (41%) of the 22 patients.
All the patients in this group seroconverted after
30 days, becoming either IgM- or IgG-positive for
HSV-1; one patient remained positive only for
IgM by BioPlex after 89 days.
Diamedix IgM test results were equivocal for six
(23%) of the 26 sera taken during the ﬁrst 30 days
of HSV-1 infection. Of the remaining 20 sera, ﬁve
had IgM only by Diamedix (Table 2). Among the
17 patients with deﬁnitive results, seroconversion
to HSV-1 was observed in four (24%) patients by
IgG and in nine (53%) patients by IgG or IgM
within the ﬁrst 30 days (data not shown).
Detection of IgM and IgG in early HSV-2
infections
Of 40 sera obtained from 30 patients within
30 days of a ﬁrst episode of genital HSV-2, an
additional ten sera were positive for IgM only by
BioPlex IgM (Table 3). Addition of IgM testing
increased the sensitivity for detecting seroconver-
sion among the 30 patients from 14 (47%)
patients, when only BioPlex IgG was used, to 21
(70%) patients when the IgM test was added.
Diamedix IgM and Focus HSV-2 IgG ELISAs
were also applied to these sera (Table 4). Equivo-
cal results were obtained by Diamedix IgM for
one mid-phase serum and for two late-phase sera.
Table 1. BioPlex IgM and IgG test results with sera










(> 30 days) Total
– ⁄ – 11 4 0 15
+ ⁄ – 1 6 1 8
+ ⁄+ 1 3 7 11
– ⁄+ 0 0 0 0
Total 13 13 8 34
aMedian 91 days (range 31–123 days).
Table 2. Diamedix IgM and Focus HSV-1 ELISA IgG test
results with sera obtained following ﬁrst episodes of
genital herpes simplex virus-1 (HSV-1) infection
Result
IgM ⁄ IgG






(> 30 days) Total
– ⁄ – 7 3 0 10
+ ⁄ – 2 3 0 5
+ ⁄+ 2 2 5 9
– ⁄+ 0 1 1 2
Total 11 9 6 26
aEight (23%) of 34 sera (two early-phase, four mid-phase and two late-phase) were
equivocal by Diamedix IgM and are not included in this table.
Table 3. BioPlex IgM and IgG test results with sera
obtained following ﬁrst episodes of genital herpes simplex
virus-2 (HSV-2) infection, compared with recurrent epi-
sodes of genital HSV-2 infections
Result
IgM ⁄ IgG









– ⁄ – 13 0 0 0 13
+ ⁄ – 9 1 1 0 11
+ ⁄+ 3 12 8 18 41
– ⁄+ 2 0 3 37 42
Total 27 13 12 55 107
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Of the 39 sera taken within 30 days, ten were
IgM-positive only by the Diamedix ELISA and
were seronegative by Focus HSV-2 IgG. Addition
of Diamedix IgM testing increased the sensitivity
for detecting seroconversion among the 30 pa-
tients from 12 (40%) by Focus HSV-2 ELISA to 21
(70%) when the IgG and IgM tests were both
used.
With either HSV-2 test combination, the speed
of IgM or IgG appearance was not affected by the
subjects’ HSV-1 IgG serostatus at the onset of the
presenting episode.
Discriminating initial HSV-2 infection from
established HSV-2 infection
If IgM is a marker of new infection, IgM should be
present in sera taken during seroconversion, but
not in sera from patients with recurrent episodes.
To test this hypothesis, 55 sera were selected from
48 individuals who were sampled during or
immediately following (within 21 days) recurrent
HSV-2 episodes. Forty-three individuals were
tested during a single recurrence, three were
tested during two separate recurrences (>4
months apart), and two were tested during three
separate recurrences (>4 months apart). All 48
subjects had established HSV-2 infections of at
least 6 months’ duration. IgM was detected, along
with IgG, in sera from 18 (33%) of 55 sera taken at
the time of a recurrent episode. Similarly, 38% of
sera taken within 30 days of an initial episode had
IgM and IgG. Thus, if both IgM and IgG are
present, the genital herpes symptoms could be
caused by either initial or recurrent infection. Two
(7%) of 30 subjects with newly acquired HSV-2 in
this study had only IgG, leading to possible
misclassiﬁcation as recurrent herpes episodes.
When the Diamedix IgM and Focus HSV-2 IgG
ELISA test combination was used, ten (26%) of 39
sera were positive only for IgM when taken
within 30 days of a ﬁrst episode, while 35 (71%)
of 49 were only positive for IgG by Focus HSV-2
ELISA during a recurrent episode. Thirteen (33%)
of the 39 early- or mid-phase ﬁrst episode sera
had both IgM and IgG, while 14 (29%) of 49 sera
from recurrent episodes had both IgM and IgG.
Thirteen (30%) of 44 patients with recurrent
episodes had both IgG and IgM, and could
therefore be interpreted as having a new infection
according to this test combination. Conversely,
four (13%) of 30 individuals with ﬁrst episodes
were only IgG-positive and could be diagnosed
as having an established infection. Neither the
BioPlex test combination nor the Focus ⁄Diamedix
combination was highly accurate in discrimin-
ating ﬁrst episodes from recurrent episodes.
DISCUSSION
Serological assays for HSV-1 and HSV-2 diagnosis
are still under-utilised for identifying patients
with genital herpes infections that have not been
detected by viral culture, antigen detection or PCR
techniques [8]. Serology is also the only practical
way to diagnose HSV infection in individuals
without any relevant clinical history or presenta-
tion with lesions [9,10]. Evidence is mounting for
the role of HSV-2 in the acquisition or transmission
of human immunodeﬁciency virus, resulting in an
urgent need to develop algorithms that allow the
deﬁnitive diagnosis of HSV-2 infection [11–13].
Diagnosis and typing of HSV genital infection
allows the rational application of antiviral therapy
[14] or counselling for behavioural adjustments
such as condom use [15], both of which have been
shown to reduce the risk of transmission of HSV-2.
Patients presenting to sexually transmitted disease
clinics may request HSV testing, or may assume
that such testing is included in sexually transmit-
ted disease screening [16–18].
Testing strategies to detect antibodies to HSV-2
in patients with an atypical presentation, or to
diagnose genital HSV-1 and HSV-2 in sympto-
matic individuals, have emphasised detection of
HSV IgG [19,20], and tests based on the type-
speciﬁc proteins gG-1 and gG-2 have been recom-
mended because of extensive cross-reactivity of
antibodies to HSV-1 and HSV-2 [21]. The present
study provides initial data on the performance of
Table 4. Diamedix IgM and Focus HSV-2 ELISA IgG
results with sera obtained following ﬁrst episodes of
genital herpes simplex virus-2 (HSV-2) infection, com-
pared with recurrent episodes of genital HSV-2 infections
Result
IgM ⁄ IgG









– ⁄ – 12 0 1 0 13
+ ⁄ – 8 2 0 0 10
+ ⁄+ 4 9 8 14 35
– ⁄+ 3 1 1 35 40
Total 27 12 10 49 98
aNine (8%) sera (one mid-phase, two late-phase, and six sera from recurrent
episodes) generated equivocal results by Diamedix and are not included in this
table.
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a novel test format for gG-speciﬁc antibodies to
HSV-1 and HSV-2. BioPlex HSV-1 and HSV-2 IgG
test results were compared with those obtained
by Focus HerpeSelect, the only licensed gG-based
ELISAs available at the time of the study.
Overall concordance for the HSV-1 BioPlex and
Focus HSV-1 tests, and also for the HSV-2 BioPlex
and Focus HSV-2 tests, was 95%. While these data
are limited to 216 anonymised sera for which
clinical or demographic data were not available,
the BioPlex HSV-1 and HSV-2 IgG tests appeared
to be comparable in performance with the Focus
tests. When compared with WB, the BioPlex and
Focus tests for HSV-1 IgG were less sensitive but
equally speciﬁc; HSV-2 speciﬁcity was lower with
Focus IgG than with BioPlex IgG compared with
WB. It was not possible to determine whether the
discordant results were caused by early serocon-
version. The sera were from patients at risk for
having early infection; 40% of the sera sent to the
University of Washington laboratory are HSV-2
seropositive (personal unpublished data).
The clinical sensitivity of the BioPlex tests for
IgG to HSV-1 or HSV-2 was determined using
sera from virologically and serologically deﬁned
ﬁrst episodes of symptomatic genital herpes.
Subject history, culture results from lesions, and
WB testing of sera taken during and following the
presenting episode, were used to verify that the
individuals in this group were newly infected
with either HSV-1 or HSV-2. Focus IgG ELISA
was used as a comparator test for detection of
early seroconversion by BioPlex IgG. Sera taken
during the ﬁrst 30 days following onset of genital
HSV-1 were predominantly false-negative by both
BioPlex and Focus HSV-1 IgG tests (85% and
77%, respectively). Previous studies on a more
extensive set of sera revealed a median time to
seroconversion by Focus HSV-1 ELISA of 25 days;
thus, only c. 50% of patients in the previous study
yielded false-negative results at 25 days [22]. This
comparison suggests that the small group of HSV-
1 seroconverters used in the present study may
have included a high proportion of patients who
required a longer time for seroconversion than
was identiﬁed in the previous study.
HSV-2 seroconversion was detected within
30 days in a higher proportion of sera (43%) than
was seen in HSV-1 patients. A previous study
revealed a median time to seroconversion of 21–
23 days by Focus HSV-2 ELISA [22]. The time-to-
seroconversion estimates for the two separate
trials of the sensitivity of the Focus assay are
closer than those for HSV-1 seroconversion. In
comparison with the previous study, the BioPlex
and Focus assays both appeared to be substan-
tially more sensitive than WB for detecting early
seroconversion to HSV-2 (40–47 days for full
proﬁles to develop in 50% of subjects). The time
to WB seroconversion was not tested directly in
the present study.
Seroconversion can be detected sooner by
adding tests for IgM [19,23]. When the BioPlex
IgM test was applied to sera from culture-docu-
mented HSV-1 seroconverters, the sensitivity for
detection of early HSV-1 infection increased from
14% (i.e., subjects positive by BioPlex IgG alone)
to 41%. Use of the Diamedix IgM assay increased
the sensitivity for detection of seroconversion by
Focus HSV-1 ELISA from 24% to 53%. When both
the BioPlex IgG and IgM assays were used, HSV-2
seroconversion was detected in 70% of subjects,
compared with 47% of subjects identiﬁed by the
BioPlex HSV-2 IgG assay alone. The Diamedix
IgM assay and the Focus HSV-2 ELISA detected
seroconversion in 70% of subjects, compared with
only 40% detected by IgG testing alone. Four
patients were positive only for IgG during the
ﬁrst week of HSV-2 infection (two by BioPlex and
an additional two by the Diamedix ⁄Focus combi-
nation). None of these four patients was positive
for HSV-2 by WB, but two were positive for HSV-
1 antibodies, and three of four seroconverted to
HSV-2 during or after the present study; the
fourth did not return for follow-up care. It is
possible that the gG-based IgG tests are more
sensitive than IgM or WB [22]. Thus, tests for IgM
in the early weeks following symptomatic genital
HSV-1 or HSV-2 infection markedly increased the
detection of seroconversion.
Clinicians may regard IgM as an accurate
marker for newly acquired HSV-2 infection.
However, only a minority of HSV-2 patients (nine
of 30 by BioPlex; ten of 30 by Diamedix ⁄Focus)
were positive only for IgM early (<30 days)
during their ﬁrst episode. A substantial propor-
tion of newly infected subjects had either IgG
alone, or both IgG and IgM (18 of 30 by BioPlex;
12 of 30 by Focus ⁄Diamedix). Of 55 sera from 55
separate recurrent episodes of HSV-2 genital
herpes, 18 (33%) had IgM to HSV-2 by BioPlex
and 29% (14 ⁄ 49) were IgM-positive by Diamedix.
These data are similar to those obtained with a
prototype type-speciﬁc IgM test [19]. Thus, use of
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IgM results from any of several methods appears
to be ineffective at discriminating early from
established infections and should not be relied
upon for this purpose.
In summary, the results obtained with the
BioPlex IgG assays showed high concordance
with the results obtained by the Focus HSV-1 and
HSV-2 ELISAs. The completely automated format
makes the BioPlex IgG tests a good alternative to
ELISAs for high-throughput testing, either for a
diagnostic service or for seroepidemiological
studies. BioPlex tests require 40 min to generate
the ﬁrst result, with an hourly throughput of
c. 100 tests. The ability to add other analytes
within the system may allow the use of screening
panels within a single test run, e.g., a genital ulcer
panel of HSV-1, HSV-2 and syphilis. The multi-
analyte testing format provides a cost-effective
means for laboratories to offer both IgM and IgG
tests if the BioPlex 2200 is used for HSV tests.
However, equipment cost will probably restrict
the use of these tests to laboratories that use the
BioPlex 2200 system for most of their serological
testing. IgM tests have the potential to identify
sera from patients undergoing seroconversion,
but can be considered deﬁnitive evidence for new
infection only in those patients who are negative
for IgG. The high prevalence of positive IgM
results among patients with recurrent episodes
appears to be a biological phenomenon that
limits the utility of IgM tests for HSV in identi-
fying new infections to which IgG has not yet
been elicited.
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